These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18679625)

  • 1. Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia.
    Doering CB
    Methods Mol Biol; 2008; 433():203-12. PubMed ID: 18679625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
    Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
    Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium.
    Gnecchi M; Melo LG
    Methods Mol Biol; 2009; 482():281-94. PubMed ID: 19089363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for hemophilia.
    Lynch CM
    Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter.
    Picanço V; Heinz S; Bott D; Behrmann M; Covas DT; Seifried E; Tonn T
    Cytotherapy; 2007; 9(8):785-94. PubMed ID: 17917890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells.
    Herder C; Tonn T; Oostendorp R; Becker S; Keller U; Peschel C; Grez M; Seifried E
    Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2266-72. PubMed ID: 14551158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
    Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
    J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy strategies for hemophilia: benefits versus risks.
    Petrus I; Chuah M; VandenDriessche T
    J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
    Van Damme A; Chuah MK; Collen D; VandenDriessche T
    Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
    Liu L; Mah C; Fletcher BS
    Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for hemophilia A.
    Connelly S; Kaleko M
    Thromb Haemost; 1997 Jul; 78(1):31-6. PubMed ID: 9198123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
    Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
    Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High level expression of human factor VIII in mammalian cells after retroviral-mediated gene transfer.
    Guo X; Wang H; Chu H; Wang X; Qu B; Li Z; Qi Z; Wang Z
    Chin Med J (Engl); 2001 Jul; 114(7):690-3. PubMed ID: 11780328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy.
    Youjin S; Jun Y
    Biotechnol Lett; 2009 Mar; 31(3):321-8. PubMed ID: 18979215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosynthesis of FVIII in megakaryocytic cells: improved production and biochemical characterization.
    Rodriguez MH; Plantier JL; Enjolras N; Réa M; Leboeuf M; Uzan G; Négrier C
    Br J Haematol; 2004 Dec; 127(5):568-75. PubMed ID: 15566360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer as an approach to treating hemophilia.
    High KA
    Semin Thromb Hemost; 2003 Feb; 29(1):107-20. PubMed ID: 12640573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical gene transfer studies for hemophilia A.
    Chuah MK; Collen D; VandenDriessche T
    Semin Thromb Hemost; 2004 Apr; 30(2):249-56. PubMed ID: 15118936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.